NO20014524L - Rekombinant IL-18 antagonister anvendelige i behandling av IL- 18 medierte forstyrrelser - Google Patents

Rekombinant IL-18 antagonister anvendelige i behandling av IL- 18 medierte forstyrrelser

Info

Publication number: NO20014524L
Authority: NO; Norway
Prior art keywords: recombinant; treatment; mediated disorders; antagonists useful; antagonists
Prior art date: 1999-03-19

Application number

NO20014524A

Other languages

English (en)

Other versions

NO20014524D0 (no

NO330391B1 (no

Inventor

Stephen D Holmes

Yen Sen Ho

Alexander Harrison Taylor

Sherin S Abdel-Meguid

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-19

Filing date

2001-09-18

Publication date

2001-11-14

2001-09-18 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2001-09-18 Publication of NO20014524D0 publication Critical patent/NO20014524D0/no

2001-11-14 Publication of NO20014524L publication Critical patent/NO20014524L/no

2011-04-04 Publication of NO330391B1 publication Critical patent/NO330391B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO20014524A 1999-03-19 2001-09-18 Immunoglobulin og isolert nukleinsyremolekyl kodende for immunoglobulin komplementaritetsbestemmende region NO330391B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12529999P	1999-03-19	1999-03-19
PCT/US2000/007349 WO2000056771A1 (en)	1999-03-19	2000-03-17	Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders

Publications (3)

Publication Number	Publication Date
NO20014524D0 NO20014524D0 (no)	2001-09-18
NO20014524L true NO20014524L (no)	2001-11-14
NO330391B1 NO330391B1 (no)	2011-04-04

Family

ID=22419067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20014524A NO330391B1 (no)	1999-03-19	2001-09-18	Immunoglobulin og isolert nukleinsyremolekyl kodende for immunoglobulin komplementaritetsbestemmende region

Country Status (28)

Country	Link
US (2)	US6706487B1 (no)
EP (2)	EP1163271B1 (no)
JP (1)	JP2002542769A (no)
KR (1)	KR100697120B1 (no)
CN (1)	CN1246335C (no)
AR (1)	AR022952A1 (no)
AT (1)	ATE402191T1 (no)
AU (1)	AU764622B2 (no)
BR (1)	BR0008688A (no)
CA (1)	CA2368965C (no)
CO (1)	CO5470287A1 (no)
CY (1)	CY1108387T1 (no)
CZ (1)	CZ303704B6 (no)
DE (1)	DE60039589D1 (no)
DK (1)	DK1163271T3 (no)
ES (1)	ES2308974T3 (no)
HK (1)	HK1043798B (no)
HU (1)	HU228931B1 (no)
IL (1)	IL144995A0 (no)
MY (1)	MY124219A (no)
NO (1)	NO330391B1 (no)
NZ (1)	NZ513699A (no)
PL (1)	PL202396B1 (no)
PT (1)	PT1163271E (no)
SI (1)	SI1163271T1 (no)
TR (3)	TR200102733T2 (no)
WO (1)	WO2000056771A1 (no)
ZA (1)	ZA200107639B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5852266A (en) *	1993-07-14	1998-12-22	Hitachi, Ltd.	Vacuum circuit breaker as well as vacuum valve and electric contact used in same
IL121860A0 (en)	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
US7704944B2 (en)	1997-08-14	2010-04-27	Yeda Research And Development Company Ltd.	Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en)	1997-08-14	2007-05-22	Yeda Research And Development Company Ltd.	Interleukin-18 binding proteins, their preparation and use
CA2276216A1 (en) *	1998-06-24	1999-12-24	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) *	1999-03-19	2002-09-04	Smithkline Beecham Corp	ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7229619B1 (en)	2000-11-28	2007-06-12	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU785038B2 (en) *	2000-01-27	2006-08-31	Applied Molecular Evolution, Inc.	Ultra high affinity neutralizing antibodies
SK12942002A3 (sk) *	2000-02-10	2003-05-02	Abbott Laboratories	Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
ME00546B (me) *	2000-02-21	2011-10-10	Serono Lab	Korišćenje inhibitora il-18
AU2002224417A1 (en) *	2000-10-18	2002-04-29	Immunex Corporation	Methods for treating il-18 mediated disorders
US7179900B2 (en)	2000-11-28	2007-02-20	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2003083071A2 (en) *	2002-03-26	2003-10-09	Centocor, Inc.	Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
AU2002343870A1 (en) *	2002-11-07	2004-06-07	Kumamoto Technology And Industry Foundation	Transgenic mammal carrying ganp and utilization thereof
KR100988129B1 (ko)	2003-04-30	2010-10-18	쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트	인간 항인간 인터루킨-18 항체와 그 단편, 및 이들의이용방법
US20050100965A1 (en) *	2003-11-12	2005-05-12	Tariq Ghayur	IL-18 binding proteins
US7968684B2 (en) *	2003-11-12	2011-06-28	Abbott Laboratories	IL-18 binding proteins
AU2011224023C1 (en) *	2003-11-12	2013-08-29	Abbvie Inc.	IL-18 binding proteins
US7141382B1 (en)	2004-10-12	2006-11-28	Parikh Chirag R	Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
US7910708B2 (en)	2005-10-21	2011-03-22	Novartis Ag	Anti-IL13 human antibodies
TWI422387B (zh) *	2006-05-25	2014-01-11	Glaxo Group Ltd	免疫球蛋白
GB0610438D0 (en) *	2006-05-25	2006-07-05	Glaxo Group Ltd	Immunoglobulins
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
EP2238166B1 (en)	2007-10-05	2013-11-27	Genentech, Inc.	Use of anti-amyloid beta antibody in ocular diseases
EP2210901A4 (en) *	2007-10-19	2012-04-25	Immunas Pharma Inc	FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE
US20100291071A1 (en) *	2008-08-01	2010-11-18	Immunas Pharma, Inc.	Antibody Specific Binding to A-Beta Oligomer and the Use
SG188116A1 (en) *	2008-02-08	2013-03-28	Immunas Pharma Inc	Antibody capable of binding specifically to ab-oligomer, and use thereof
EP2281004A4 (en) *	2008-04-14	2012-02-15	Proscan Rx Pharma Inc	PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
US9085614B2 (en)	2008-08-01	2015-07-21	Immunas Pharma, Inc.	Antibodies that specifically bind to Aβ oligomers and uses thereof
EP2326315A1 (en) *	2008-08-18	2011-06-01	Glaxo Group Limited	Treatment of an autoimmune disease using il-18 antagonists
WO2010040736A2 (en) *	2008-10-07	2010-04-15	Ablynx Nv	Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US8168165B2 (en)	2008-12-23	2012-05-01	Abbott Laboratories	Alkylated interleukin-18 compositions
US9090679B2 (en)	2009-04-17	2015-07-28	Immunas Pharma, Inc.	Antibodies that specifically bind to A beta oligomers and use thereof
US20110136601A1 (en) *	2009-06-30	2011-06-09	Gosen Co., Ltd.	Racket string and method for producing the same and racket strung with the same
CN102574915B (zh)	2009-08-06	2014-10-22	伊缪纳斯制药株式会社	特异性结合Aβ寡聚体的抗体及其用途
CN102596997B (zh)	2009-08-06	2015-06-03	伊缪纳斯制药株式会社	特异性结合Aβ寡聚体的抗体及其用途
JP5903382B2 (ja)	2009-08-29	2016-04-13	アッヴィ・インコーポレイテッド	治療用ｄｌｌ４結合タンパク質
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
EP2534175A2 (en) *	2010-02-09	2012-12-19	Glaxo Group Limited	Treatment of a metabolic disorder
EP2538965B1 (en)	2010-02-25	2017-04-12	Schepens Eye Research Institute	Therapeutic compositions for the treatment of dry eye disease
BR112012021941A2 (pt) *	2010-03-02	2022-02-01	Abbvie Inc	Proteínas terapêuticas de ligação a dll4
US20130109107A1 (en) *	2010-05-25	2013-05-02	The Regents Of The University Of Colorado	Diagnosis and treatment of autoimmune disease
KR101713365B1 (ko)	2010-07-30	2017-03-08	에이씨 이뮨 에스.에이.	안전하고 기능적인 인간화 항 베타-아밀로이드 항체
BR112013015508B1 (pt)	2010-12-20	2022-04-05	Medimmune Limited	Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
JOP20200308A1 (ar)	2012-09-07	2017-06-16	Novartis Ag	جزيئات إرتباط il-18
US10570199B2 (en)	2012-11-21	2020-02-25	Km Biologics Co., Ltd.	Human antibody against IL-18
SG11201706879UA (en) *	2015-03-05	2017-09-28	Ab2 Bio Sa	Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
CA3183242A1 (en) *	2020-06-18	2021-12-23	Dallas Benjamin Flies	Compositions and methods for modulating flrt3 mediated signal transduction
EP4371573A1 (en)	2021-07-13	2024-05-22	National University Corporation Tokai National Higher Education and Research System	Medicinal composition for treating inflammatory bowel disease
WO2024261470A1 (en)	2023-06-20	2024-12-26	Apollo Ap43 Limited	Anti-il-18 antibody therapy for treating atopic dermatitis
CN117986360B (zh) *	2024-02-01	2024-08-27	生物岛实验室	Il18蛋白的特异性抗体及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU22545A1 (es) *	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
EP0528767B1 (en)	1991-08-21	2000-01-12	Novartis AG	Antibody derivatives
GB9125979D0 (en) *	1991-12-06	1992-02-05	Wellcome Found	Antibody
TW464656B (en)	1994-11-15	2001-11-21	Hayashibara Biochem Lab	Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
IL121860A0 (en) *	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
FR2767697B1 (fr)	1997-09-01	2000-05-05	Boots Co Plc	Composition dermatologique permettant d'eviter l'apparition de symptomes d'hypersensibilite et d'intolerance cutanee
CA2276216A1 (en) *	1998-06-24	1999-12-24	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) *	1999-03-19	2002-09-04	Smithkline Beecham Corp	ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL

2000
- 2000-03-16 AR ARP000101168A patent/AR022952A1/es active IP Right Grant
- 2000-03-17 CZ CZ20013362A patent/CZ303704B6/cs not_active IP Right Cessation
- 2000-03-17 AT AT00918152T patent/ATE402191T1/de active
- 2000-03-17 MY MYPI20001044A patent/MY124219A/en unknown
- 2000-03-17 KR KR1020017011872A patent/KR100697120B1/ko not_active Expired - Lifetime
- 2000-03-17 ES ES00918152T patent/ES2308974T3/es not_active Expired - Lifetime
- 2000-03-17 DK DK00918152T patent/DK1163271T3/da active
- 2000-03-17 US US09/914,695 patent/US6706487B1/en not_active Expired - Lifetime
- 2000-03-17 CO CO00019489A patent/CO5470287A1/es active IP Right Grant
- 2000-03-17 TR TR2001/02733T patent/TR200102733T2/xx unknown
- 2000-03-17 TR TR2002/02254T patent/TR200202254T2/xx unknown
- 2000-03-17 PT PT00918152T patent/PT1163271E/pt unknown
- 2000-03-17 JP JP2000606631A patent/JP2002542769A/ja active Pending
- 2000-03-17 HU HU0200502A patent/HU228931B1/hu unknown
- 2000-03-17 WO PCT/US2000/007349 patent/WO2000056771A1/en active IP Right Grant
- 2000-03-17 TR TR2002/02253T patent/TR200202253T2/xx unknown
- 2000-03-17 SI SI200031002T patent/SI1163271T1/sl unknown
- 2000-03-17 IL IL14499500A patent/IL144995A0/xx not_active IP Right Cessation
- 2000-03-17 PL PL350460A patent/PL202396B1/pl unknown
- 2000-03-17 CN CNB008077703A patent/CN1246335C/zh not_active Expired - Lifetime
- 2000-03-17 BR BR0008688-6A patent/BR0008688A/pt not_active Application Discontinuation
- 2000-03-17 NZ NZ513699A patent/NZ513699A/xx not_active IP Right Cessation
- 2000-03-17 CA CA2368965A patent/CA2368965C/en not_active Expired - Lifetime
- 2000-03-17 EP EP00918152A patent/EP1163271B1/en not_active Expired - Lifetime
- 2000-03-17 DE DE60039589T patent/DE60039589D1/de not_active Expired - Lifetime
- 2000-03-17 EP EP08157217A patent/EP1961768A1/en not_active Withdrawn
- 2000-03-17 AU AU39016/00A patent/AU764622B2/en not_active Expired
2001
- 2001-09-17 ZA ZA200107639A patent/ZA200107639B/en unknown
- 2001-09-18 NO NO20014524A patent/NO330391B1/no not_active IP Right Cessation
2002
- 2002-05-21 HK HK02103813.7A patent/HK1043798B/zh not_active IP Right Cessation
2004
- 2004-01-22 US US10/762,629 patent/US20040141964A1/en not_active Abandoned
2008
- 2008-09-30 CY CY20081101085T patent/CY1108387T1/el unknown

Also Published As

Publication number	Publication date
SI1163271T1 (sl)	2008-10-31
NO20014524D0 (no)	2001-09-18
ZA200107639B (en)	2002-09-17
CY1108387T1 (el)	2014-02-12
EP1961768A1 (en)	2008-08-27
US20040141964A1 (en)	2004-07-22
EP1163271B1 (en)	2008-07-23
DK1163271T3 (da)	2008-11-10
MY124219A (en)	2006-06-30
TR200202254T2 (tr)	2002-12-23
ES2308974T3 (es)	2008-12-16
DE60039589D1 (de)	2008-09-04
BR0008688A (pt)	2002-01-08
AU3901600A (en)	2000-10-09
AU764622B2 (en)	2003-08-28
IL144995A0 (en)	2002-06-30
HK1043798B (zh)	2009-04-09
HUP0200502A3 (en)	2003-12-29
TR200202253T2 (tr)	2002-12-23
EP1163271A4 (en)	2003-04-09
NZ513699A (en)	2004-02-27
HK1043798A1 (en)	2002-09-27
TR200102733T2 (tr)	2002-04-22
JP2002542769A (ja)	2002-12-17
CZ20013362A3 (cs)	2002-03-13
PT1163271E (pt)	2008-09-16
HUP0200502A2 (en)	2002-06-29
CA2368965A1 (en)	2000-09-28
WO2000056771A1 (en)	2000-09-28
US6706487B1 (en)	2004-03-16
CZ303704B6 (cs)	2013-03-27
PL350460A1 (en)	2002-12-16
AR022952A1 (es)	2002-09-04
ATE402191T1 (de)	2008-08-15
KR100697120B1 (ko)	2007-03-20
PL202396B1 (pl)	2009-06-30
CN1246335C (zh)	2006-03-22
CN1352650A (zh)	2002-06-05
KR20020008130A (ko)	2002-01-29
EP1163271A1 (en)	2001-12-19
HU228931B1 (en)	2013-06-28
CA2368965C (en)	2010-05-18
NO330391B1 (no)	2011-04-04
CO5470287A1 (es)	2004-12-30

Publication	Publication Date	Title
NO20014524L (no)	2001-11-14	Rekombinant IL-18 antagonister anvendelige i behandling av IL- 18 medierte forstyrrelser
CY2015056I2 (el)	2016-06-22	Ανασυνδυασμενοι antαγωνιστες της il-5 που ειναι χρησιμοι στη θεραπεια διαταραχων που διαμεσολαβουνται απο την il-5
HK1109867A1 (en)	2008-06-27	Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
NO20013340L (no)	2001-09-17	Antagonister for TWEAK og for TWEAK-reseptor samt anvendelse derav ved behandling av immunologiske lidelser
NO20040097L (no)	2004-03-01	Kombinasjoner for behandling av inflammatoriske forstyrrelser
HK1079203A1 (en)	2006-03-31	Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
DK1047428T3 (da)	2007-10-08	Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
CY2013041I2 (el)	2015-12-09	Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
DE60222671D1 (de)	2007-11-08	Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
HK1152243A1 (en)	2012-02-24	Vegf for use in the treatment of central nervous system disorders vegf
NO20022680L (no)	2002-08-12	Farmasoytiske kombinasjoner og deres anvendelse ved behandling av gastrointestinale forstyrrelser
NO20021845D0 (no)	2002-04-19	Behandling av sövnforstyrrelser under anvendelse av desloratadin
NO20034232D0 (no)	2003-09-23	Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser
NO20006113L (no)	2001-01-25	Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer
NO20031525L (no)	2003-04-03	Kjemokinmutanter i behandlingen av multippel sklerose
NO20023803D0 (no)	2002-08-09	Anvendelse av mirtazapin for behandling av sövnforstyrrelser
NO20020008D0 (no)	2002-01-02	Anvendelse av cortisol antagonister i behandling av hjertesvikt
PT1178981E (pt)	2003-11-28	3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
NO20005216D0 (no)	2000-10-17	Sammensetning for behandling av eksterne sekresjonssykdommer unntatt hypolakrimasjon
ID30458A (id)	2001-12-06	Osanetan dalam pengobatan gangguan jiwa
DE60323960D1 (de)	2008-11-20	Enzen 900 und 1800 mhz
NO20012612D0 (no)	2001-05-28	Isonipecotamider for behandling av integren-formidlede lidelser
IS2153B (is)	2006-10-13	S-nítrósóþíól til meðferðar við blóðrásartruflunum
FI20002612A0 (fi)	2000-11-28	Yhdistelmäterapia serotoniinivälityksen häiriöiden hoitamiseksi
NO20040935L (no)	2004-06-04	Plaster for behandling av dysfunksjoner og forstyrrelser i negler.

Legal Events

Date	Code	Title	Description
2017-11-27	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: SMITHKLINE BEECHAM PLC, US
2020-04-14	MK1K	Patent expired